

10074220

0430
#2


FULBRIGHT & JAWORSKI L.L.P.
A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

TELEPHONE: 512/536-5201
FACSIMILE: 512/536-5202
WRITER'S INTERNET ADDRESS:
PSUBRAMONY@FULBRIGHT.COM
WRITER'S DIRECT DIAL NUMBER:
512/536-3067

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

April 3, 2002

FILE: UTSD:771US

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
April 3, 2002	
Date	Priya D. Subramony

Commissioner for Patents
Washington, DC 20231


RE: *SN 10/074,220 "DIAGNOSIS AND TREATMENT OF INFLAMMATION AND HYPERACTIVE IMMUNE CONDITIONS" – Tadashi Kumamoto et al. (Client Reference: UTSD:0771)*

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (C1-C32).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10201672/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Priya D. Subramony
Patent Agent
Reg. No. 50,939

PDS/cmb
Encl: as noted



PATENT

UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Tadashi Kumamoto *et al.*

Serial No.: 10/074,220

Filed: February 12, 2002

For: DIAGNOSIS AND TREATMENT OF
INFLAMMATION AND HYPERACTIVE
IMMUNE CONDITIONS

Group Art Unit: Unknown

Examiner: Unknown


Atty. Dkt. No.: UTSD:771US/SLH

CERTIFICATE OF MAILING 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

April 3, 2002

Date


Priya D. Subramony

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10201672/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Priya D. Subramony
Reg. No. 50,939
Agent for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: April 3, 2002

Form PTO-1449 (modified)

Atty. Docket No.

UTSD:771US/SLH

Serial No.

10/074,220

Office of Patents and Publications for Applicant's

Applicant

Tadashi Kumamoto *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

February 12, 2002

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Berchtold <i>et al.</i> , "Human monocyte derived dendritic cells express functional P2X and P2Y receptors as well as ecto-nucleotidases," <i>FEBS Lett.</i> , 458:424-428, 1999.
	C2	Betto, <i>et al.</i> , "Ecto-ATPase activity of alpha-sarcoglycan (adhelin)" <i>J. Biol. Chem.</i> , 274: 7907-7912, 1999.
	C3	Biederbick, <i>et al.</i> , "A human intracellular apyrase-like protein, LALP70, localizes to lysosomal/autophagic vacuoles," <i>J. Cell Sci.</i> , 112: 2473-2484, 1999.
	C4	Chadwick and Frischauf, "The CD39-like gene family: identification of three new human members (CD39L2, CD39L3, and CD39L4), their murine homologues, and a member of the gene family from <i>Drosophila melanogaster</i> ," <i>Genomics</i> , 50:357-367, 1998.
	C5	Coutinho-Silva <i>et al.</i> , "P2Z/P2X7 receptor-dependent apoptosis of dendritic cells," <i>Am. J. Physiol.</i> 276:C1139-C1147, 1999.
	C6	Di Virgilio, <i>et al.</i> , "Nucleotide receptors: an emerging family of regulatory molecules in blood cells," <i>Blood</i> , 97: 587-600, 2001.
	C7	Dumbrowski <i>et al.</i> , "Ecto-ATPase: an activation marker necessary for effector cell function," <i>Immunol Rev.</i> , 161:111-118, 1998.
	C8	Effendy, <i>et al.</i> , "Epidermal cytokines in murine cutaneous irritant responses," <i>J. Appl. Toxicol.</i> , 20: 335-341, 2000.

25144084.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

 Atty. Docket No.
 UTSD:771US/SLH

 Serial No.
 10/074,220

List of Patents and Publications for Applicant's

 Applicant
 Tadashi Kumamoto *et al.*

INFORMATION DISCLOSURE STATEMENT

 Filing Date:
 February 12, 2002

 Group:
 Unknown

(Use several sheets if necessary)

 U.S. Patent Documents
 See Page 1

 Foreign Patent Documents
 See Page 1

 Other Art
 See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Enjoji, <i>et al.</i> "Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation," <i>Nat. Med.</i> , 5:1010-1017, 1999.
	C10	Ferrari, <i>et al.</i> "The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release," <i>FASEB J.</i> , 14: 2466-2476, 2000.
	C11	Filippini, <i>et al.</i> , "Extracellular ATP in T-lymphocyte activation: possible role in effector functions," <i>Proc. Natl. Acad. Sci. U. S. A.</i> , 87: 8267-8271, 1990.
	C12	Girolomoni <i>et al.</i> , "Epidermal Langerhans cells are resistant to the permeabilizing effects of extracellular ATP: in vitro evidence supporting a protective role of membrane ATPase," <i>J. Invest Dermatol.</i> , 100:282-287, 1993.
	C13	Heine, <i>et al.</i> , "Functional characterization of rat ecto-ATPase and ecto-ATP diphosphohydrolase after heterologous expression in CHO cells," <i>Eur J Biochem.</i> , 262(1):102-107, 1999.
	C14	Imai, <i>et al.</i> , "CD39 modulates IL-1 release from activated endothelial cells," <i>Biochem. Biophys. Res. Commun.</i> , 270: 272-278, 2000.
	C15	Knowles and Nagy, "Inhibition of an ecto-ATP-diphosphohydrolase by azide," <i>Eur. J. Biochem.</i> , 262:349-357, 1999.
	C16	Liu <i>et al.</i> "Expression and a role of functionally coupled P2Y receptors in human dendritic cells," <i>FEBS Lett.</i> , 445:402-408, 1999.
	C17	Marriott, <i>et al.</i> , "Extracellular uridine nucleotides initiate cytokine production by murine dendritic cells," <i>Cell. Immunol.</i> , 195:147-156, 1999.
	C18	Matsue <i>et al.</i> , "Induction of antigen-specific immunosuppression by CD95L cDNA-transfected "killer" dendritic cells," <i>Nature Med.</i> , 5:930-937, 1999.
	C19	Matsue, <i>et al.</i> , "Keratinocyte-derived IL-7 serves as a growth factor for dendritic epidermal T-cells in mice," <i>J. Immunol.</i> , 151:6012-6019, 1993.
	C20	Mummert, <i>et al.</i> , "Development of a peptide inhibitor of hyaluronan-mediated leukocyte trafficking," <i>J. Exp. Med.</i> , 192:769-779, 2000.
	C21	Mutini <i>et al.</i> , "Mouse dendritic cells express the P2X ₇ purinergic receptor: characterization and possible participation in antigen presentation," <i>J. Immunol.</i> , 163:1958-1965, 1999.

25144084.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.
UTSD:771US/SLHSerial No.
10/074,220

List of Patents and Publications for Applicant's

Applicant
Tadashi Kumamoto *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
February 12, 2002Group:
UnknownU.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C22	Nihei, <i>et al.</i> , "Pharmacologic properties of P ₂₂ /P2X ₇ receptor characterized in murine dendritic cells: role on the induction of apoptosis," <i>Blood</i> , 96: 996-1005, 2000.
	C23	Ralevic and Burnstock, "Receptors for purines and pyrimidines," <i>Pharmacol. Rev.</i> 50:413-492, 1998.
	C24	Sellers, <i>et al.</i> , "Adenosine nucleotides acting at the human P2Y1 receptor stimulate mitogen-activated protein kinases and induce apoptosis," <i>J. Biol. Chem.</i> , 276: 16379-16390, 2001.
	C25	Sevigny, <i>et al.</i> , "Identification and characterization of a novel hepatic canalicular ATP diphosphohydrolase," <i>J. Biol. Chem.</i> , 275: 5640-5647, 2000.
	C26	Wang, and Guidotti, "Golgi localization and functional expression of human uridine diphosphatase," <i>J. Biol. Chem.</i> , 273: 11392-11399, 1998.
	C27	Warny, <i>et al.</i> , "P2Y(6) nucleotide receptor mediates monocyte interleukin-8 production in response to UDP or lipopolysaccharide," <i>J. Biol. Chem.</i> , 276: 26051-26056, 2001.
	C28	Williams and Jarvis, "Purinergic and pyrimidinergic receptors as potential drug targets," <i>Biochem. Pharmacol.</i> , 59:1173-1185, 2000.
	C29	Xu, <i>et al.</i> , "Successive generation of antigen-presenting, dendritic cell lines from murine epidermis," <i>J. Immunol.</i> , 154:2697-2705, 1995.
	C30	Zhong and Guidotti, "A yeast Golgi E-type ATPase with an unusual membrane topology," <i>J. Biol. Chem.</i> , 274:32704-32711, 1999.
	C31	Ziganshina, <i>et al.</i> , "Acute paw oedema formation induced by ATP: re-evaluation of the mechanisms involved," <i>Inflamm. Res.</i> , 45: 96-102, 1996.
	C32	Zinchuk <i>et al.</i> , "Ecto-ATPase activity in cerebellum: implication to the function of synaptic transmission," <i>Brain Res.</i> 815:111-115, 1999.

25144084.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)